Preferential binding of adriamycin and nogalamycin to DNase-I hypersensitive sites of Sarcoma-180 chromatin.
Binding of nogalamycin and adriamycin with Sarcoma-180 ascites tumor cell chromatin was studied by a spectrofluorometric method. There was significant reduction in the number of available drug binding sites per nucleotide when the chromatin was digested with DNase I for a period which releases only 7% of the chromosomal DNA. Results indicate preferential binding of these drugs with DNase I hypersensitive sites of chromatin. The DNase-I hypersensitive sites of chromatin were shown to correlate to the sequences required for gene expression. Further digestion with DNase I increases availability of drug binding sites, probably due to relaxation of the compact chromatin.
D000818:Animals; D001665:Binding Sites; D002843:Chromatin / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000378:metabolism; D003630:Daunorubicin / Q000031:analogs & derivatives*; D003850:Deoxyribonuclease I / Q000378:metabolism*; D004317:Doxorubicin / Q000378:metabolism*; D051379:Mice; D009621:Nogalamycin / Q000378:metabolism*; D012510:Sarcoma 180 / Q000378:metabolism*; D013050:Spectrometry, Fluorescence; D013816:Thermodynamics
D002843:Chromatin; D004273:DNA, Neoplasm; D004317:Doxorubicin; D003850:Deoxyribonuclease I; D009621:Nogalamycin; D003630:Daunorubicin